Is BioVie's Bezisterim Poised for a Breakthrough in Neurodegenerative Diseases

Related Articles

Is TeraDrill (TDRL) Poised for a Breakthrough in Mining Automation

3 months ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

5 months ago

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

5 months ago

Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment

3 months ago

Category

You may also like

Stock News•1 week ago

Renew Biotechnologies Publishes Peer-Reviewed Research Advancing Cell-Type-Associated Biomarkers of Neurodegeneration

Renew Biotechnologies published peer-reviewed research in Frontiers in Neurology advancing cell-type-associated biomarkers for neurodegeneration, potentially strengthening its diagnostic platform and ...

Share

Stock News•1 week ago

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

BioVie's bezisterim met Phase 2 SUNRISE-PD endpoints, showing statistically significant motor and non-motor symptom improvements versus placebo in early Parkinson's disease, plus reduced neurodegenera...

BIVI

Share

Stock News•1 months ago

Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details

Biogen stock was upgraded to Buy ahead of detailed data on its experimental Alzheimer's drug, which the market is expected to cheer.

BIIB

Share

News•2 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Pharmaceutical companies are testing new methods to bypass the blood-brain barrier for Alzheimer's treatments. Results from these delivery initiatives are expected to emerge throughout this year, pote...

Share